Sanofi: Diabetes guidance is updated and now what are we left with?

BUY, Fair Value EUR96 vs. EUR103 (+6%)
News published on October Friday 30, 2015
Share on
Once the adjustment for the new guidance in Diabetes is factored in, the question to ask is whether there is any growth left at the earnings level at Sanofi over the period 2015-2018? Under our scenario and revised figures, it would be less than 5% by 2018. We think it is reasonable to wait until November the 6th and the MMM before deciding whether it is worth buying at the current level.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities